Results 281 to 290 of about 551,808 (299)

Breakthrough-Therapy Designation — An FDA Perspective

New England Journal of Medicine, 2018
Amy E Mckee
exaly  

The FDA Breakthrough-Drug Designation — Four Years of Experience

New England Journal of Medicine, 2018
Jonathan J Darrow
exaly  

Califf for the FDA

New England Journal of Medicine, 2016
Jeffrey M Dražen, Dražen Jeffrey M
exaly  

Doxil® — The first FDA-approved nano-drug: Lessons learned

Journal of Controlled Release, 2012
Yechezkel Barenholz
exaly  

Tobacco, Public Health, and the FDA

New England Journal of Medicine, 2009
Gregory D Curfman, Stephen Morrissey, Jeffrey M Dražen   +2 more
exaly  

The FDA and Genomic Tests — Getting Regulation Right

New England Journal of Medicine, 2015
Barbara J Evans, Wylie Burke, Gail P Jarvik   +2 more
exaly  

Innovation, Regulation, and the FDA

New England Journal of Medicine, 2010
exaly  

The FDA, Politics, and Plan B

New England Journal of Medicine, 2004
Jeffrey M Dražen, Alastair J J Wood, Dražen Jeffrey M   +2 more
exaly  

FDA section

American Intra-Ocular Implant Society Journal, 1978
openaire   +2 more sources

FDA Regulation of Prescription Drugs

New England Journal of Medicine, 2017
exaly